This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Adefovir
Accession Number
DB13868
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • 9-(2-(phosphonomethoxy)ethyl)adenine
  • 9-(2-phosphonylmethoxyethyl)adenine
  • Adéfovir
  • Adefovir
  • Adefovirum
External IDs
GS 0393 / GS-0393
Categories
UNII
6GQP90I798
CAS number
106941-25-7
Weight
Average: 273.1857
Monoisotopic: 273.062690409
Chemical Formula
C8H12N5O4P
InChI Key
SUPKOOSCJHTBAH-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
IUPAC Name
{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid
SMILES
NC1=C2N=CN(CCOCP(O)(O)=O)C2=NC=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
ADNA polymerase/reverse transcriptase
inhibitor
HBV-D
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Adefovir is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Adefovir is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Adefovir is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Adefovir.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Adefovir is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Adefovir is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Adefovir.Approved
FingolimodAdefovir may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Adefovir is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Adefovir is combined with GI-5005.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Adefovir is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Adefovir is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Adefovir is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when Adefovir is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Adefovir is combined with INGN 225.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Adefovir is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
LeflunomideThe risk or severity of adverse effects can be increased when Adefovir is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Adefovir is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Adefovir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adefovir.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Adefovir is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adefovir.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Adefovir is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Adefovir.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Adefovir is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Adefovir is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Adefovir is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Adefovir is combined with Salmonella typhi ty21a live antigen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adefovir.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Adefovir is combined with SRP 299.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Adefovir.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Adefovir is combined with Tecemotide.Investigational
TG4010The risk or severity of adverse effects can be increased when Adefovir is combined with TG4010.Investigational
TofacitinibAdefovir may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Adefovir.Approved, Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Adefovir is combined with Typhoid Vaccine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Adefovir is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Adefovir is combined with Yellow Fever Vaccine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChEBI
2469
HET
5HG
Wikipedia
Adefovir
PDB Entries
2g1a

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.02 mg/mLALOGPS
logP-1.8ALOGPS
logP-4.5ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)1.35ChemAxon
pKa (Strongest Basic)5.12ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area136.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity63.12 m3·mol-1ChemAxon
Polarizability23.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
6-aminopurines
Alternative Parents
Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Organic phosphonic acids / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds
show 2 more
Substituents
6-aminopurine / Aminopyrimidine / N-substituted imidazole / Pyrimidine / Imidolactam / Azole / Imidazole / Organophosphonic acid / Organophosphonic acid derivative / Heteroaromatic compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
HBV-D
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ri...
Gene Name
P
Uniprot ID
P24024
Uniprot Name
Protein P
Molecular Weight
93588.765 Da
References
  1. Kock J, Baumert TF, Delaney WE 4th, Blum HE, von Weizsacker F: Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology. 2003 Dec;38(6):1410-8. [PubMed:14647052]

Drug created on July 06, 2017 20:58 / Updated on January 05, 2018 13:27